𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma

✍ Scribed by Shane C. White; Paul Lorigan; Mark R. Middleton; Heather Anderson; Juan Valle; Yvonne Summers; Paul A. Burt; Ana Arance; Ron Stout; Nick Thatcher

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
124 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of carboplatin and liposo
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix
✍ Claire F. Verschraegen; John J. Kavanagh; Evelyne Loyer; Diane Bodurka-Bevers; A πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma. ## METHODS. The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starti

The addition of cisplatin to cyclophosph
The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients
✍ Thierry Urban; Claude Chastang; FranΓ§ois-Xavier Lebas; Jean-Paul Duhamel; Guy Ad πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 1 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

A randomized, controlled phase III study
A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-Ξ± maintenance therapy or observation, in small cell lung carcinoma patients with complete responses
✍ Diego Tummarello; Davide Mari; Francesco Graziano; Pierpaolo Isidori; Gianluigi πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 1 views

BACKGROUND. Studies of chemotherapy for

A randomized trial of hybrid administrat
A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up
✍ Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Haruhito Kamei; Kenichi Gemba; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 101 KB πŸ‘ 1 views

## BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to

Teniposide (VM-26) as a single drug trea
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II study of the Southwest Oncology Group
✍ Petre N. Grozea; John J. Crowley; Vikki A. Canfield; Laura Kingsbury; S. William πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

## Background: Teniposide (vm-26) was reported to have activity in small cell lung carcinoma (sclc). the authors performed a phase ii study of teniposide as a treatment for patients with previously untreated extensive sclc. ## Methods: The study was open to patients with a histologic or cytologic